GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pro Medicus Ltd (ASX:PME) » Definitions » EV-to-Revenue

Pro Medicus (ASX:PME) EV-to-Revenue : 79.39 (As of May. 02, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Pro Medicus EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Pro Medicus's enterprise value is A$11,277.4 Mil. Pro Medicus's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$142.1 Mil. Therefore, Pro Medicus's EV-to-Revenue for today is 79.39.

The historical rank and industry rank for Pro Medicus's EV-to-Revenue or its related term are showing as below:

ASX:PME' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.98   Med: 29.27   Max: 103.88
Current: 79.38

During the past 13 years, the highest EV-to-Revenue of Pro Medicus was 103.88. The lowest was 1.98. And the median was 29.27.

ASX:PME's EV-to-Revenue is ranked worse than
97.57% of 659 companies
in the Healthcare Providers & Services industry
Industry Median: 1.81 vs ASX:PME: 79.38

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-02), Pro Medicus's stock price is A$109.25. Pro Medicus's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$1.36. Therefore, Pro Medicus's PS Ratio for today is 80.45.


Pro Medicus EV-to-Revenue Historical Data

The historical data trend for Pro Medicus's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pro Medicus EV-to-Revenue Chart

Pro Medicus Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.68 47.72 89.33 46.23 53.97

Pro Medicus Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 46.23 - 53.97 -

Competitive Comparison of Pro Medicus's EV-to-Revenue

For the Health Information Services subindustry, Pro Medicus's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pro Medicus's EV-to-Revenue Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pro Medicus's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pro Medicus's EV-to-Revenue falls into.



Pro Medicus EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Pro Medicus's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=11277.439/142.054
=79.39

Pro Medicus's current Enterprise Value is A$11,277.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pro Medicus's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$142.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pro Medicus  (ASX:PME) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Pro Medicus's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=109.25/1.358
=80.45

Pro Medicus's share price for today is A$109.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$1.36.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pro Medicus EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pro Medicus's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Pro Medicus (ASX:PME) Business Description

Traded in Other Exchanges
Address
450 Swan Street, Richmond, Melbourne, VIC, AUS, 3121
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are U.S. private academic hospitals. In fiscal 2022, Pro Medicus earned 79% of revenue in North America, 16% from Australia, and the remaining 6% in Europe.